Showing results (161-170 of 177) with videos related to

Sort By:
Pageof 18
Pharmacotherapy|October 19, 2024
Use of proton pump inhibitors and risk of severe COVID-19: A case-control study in United States Medicare beneficiariesAndrew D Mosholder, Hector S Izurieta, Rongmei Zhang, et al.
The American Journal of Medicine|July 27, 2013
Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDsDaniel H Solomon, Jeffrey R Curtis, Kenneth G Saag, et al.
JAMA|November 18, 2015
Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron ProductsCunlin Wang, David J Graham, Robert C Kane, et al.
Annals of Internal Medicine|November 18, 2024
The Effect of Denosumab on Risk for Emergently Treated Hypocalcemia by Stage of Chronic Kidney Disease : A Target Trial EmulationSteven T Bird, Kate Gelperin, Elizabeth R Smith, et al.
Circulation. Cardiovascular Interventions|August 6, 2026
Linking the TVT Registry to Medicare Advantage and Fee-for-Service Claims: Feasibility, Accuracy, and Implications for Real-World Surveillance InfrastructureSean M O'Brien, Bradley G Hammill, Marie C Bradley, et al.
JAMA|January 19, 2024
Severe Hypocalcemia With Denosumab Among Older Female Dialysis-Dependent PatientsSteven T Bird, Elizabeth R Smith, Kate Gelperin, et al.
Journal of the National Cancer Institute|October 6, 2023
Trends in new and persistent opioid use in older adults with and without cancerLaura Van Metre Baum, Madhav Kc, Pamela R Soulos, et al.
JAMA Oncology|December 20, 2019
Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia: A Comparison of Treatment Outcomes in Clinical Trial Participants vs Medicare BeneficiariesSteven T Bird, Fang Tian, Natasha Flowers, et al.
JAMA Internal Medicine|October 25, 2016
Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service MedicareCunlin Wang, Robert Kane, Mark Levenson, et al.
Pharmacoepidemiology and Drug Safety|November 10, 2025
Validation of the US Food and Drug Administration's COVID-19 Disease Severity Categorization for Use in Real-World DataSilvia Perez-Vilar, Wei Hua, Andrew Kwist, et al.
Pageof 18